HT-101

Phase 2Small molecule

SSuzhou HepaThera Biotech Co., Ltd.

HT-101 is one of 17 small molecule programs targeting Chronic Hepatitis B Virus Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic Hepatitis B Virus InfectionPhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Chronic Hepatitis B Virus Infection

#DrugCompanyPhaseTrials

Emtriva

Hepsera

Virazole

CConrado Roberto Hoffmann Filho

Approved

—4

Celebrex

PPhiladelphia Eye Associates

Approved

—5

Versed

CConrado Roberto Hoffmann Filho

Approved

—6

Alinia

RRomark Laboratories L.C.

Approved

—7

Cerubidine

HHikma Pharmaceuticals LLC

Bepirovirsen

1 9

PEG-IFNα

Gilead

Phase 2

2 10

VIR-3434

VVir Biotechnology, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Chronic Hepatitis B Virus Infection

NCT07245953

Phase 1/2Active, not recruiting

Chronic Hepatitis B Virus Infection

NCT07183306

Clinical

Trials by Indication[1]

Chronic Hepatitis B Virus Infection2 trials

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 1/2·NCT07183306·86 enrolled

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 2·NCT07245953·60 enrolled

Chronic HBV Infection1 trial

This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

Completed·SSuzhou HepaThera Biotech Co., Ltd.·Phase 1·NCT06746311·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HT-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HT-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HT-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou HepaThera Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSuzhou HepaThera Biotech Co., Ltd.

HT-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Hepatitis B Virus Infection2 trials

Chronic HBV Infection1 trial

References

Drug Info

Quick Facts

Related News